Reverse cardiac remodeling and outcome after initiation of sacubitril/valsartan
JL Januzzi Jr, A Camacho, IL Piña, R Rocha… - Circulation: Heart …, 2020 - Am Heart Assoc
Cardiac remodeling is pivotal to the progression of heart failure with reduced ejection
fraction (HFrEF; left ventricular [LV] ejection fraction≤ 40%). 1 Therapies that improve …
fraction (HFrEF; left ventricular [LV] ejection fraction≤ 40%). 1 Therapies that improve …
Inhibitory Effect of Valsartan Against Progression of Left Ventricular Dysfunction After Myocardial Infarction T-VENTURE Study
H Suzuki, E Geshi, S Nanjyo, H Nakano… - Circulation …, 2009 - jstage.jst.go.jp
Background: Angiotensin-converting enzyme inhibitors (ACEI) reduce the mortality in the
chronic phase of myocardial infarction (MI), and similar effects of angiotensin receptor …
chronic phase of myocardial infarction (MI), and similar effects of angiotensin receptor …
Sacubitril/Valsartan, cardiac fibrosis, and remodeling in heart failure
A Aimo, M Emdin, AS Maisel - Journal of the American College of …, 2019 - jacc.org
Converting Enzyme [ACE] Inhibitors to Determine Impact on Global Mortality and Morbidity
in Heart Failure) subanalysis reporting that therapy with sacubitril/valsartan is associated …
in Heart Failure) subanalysis reporting that therapy with sacubitril/valsartan is associated …
[引用][C] PARADISE-MI Investigators and Committees. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction
Effects of the angiotensin‐receptor neprilysin inhibitor on cardiac reverse remodeling: meta‐analysis
Y Wang, R Zhou, C Lu, Q Chen, T Xu… - Journal of the American …, 2019 - Am Heart Assoc
Background The angiotensin‐receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was
shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of …
shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of …
The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention
J Gu, Y Wang, C Wang, J Zhang - European Journal of Internal Medicine, 2023 - Elsevier
Background In real-world clinical practice, the initiation and up-titration of sacubitril/valsartan
remain challenging due to symptomatic hypotension in patients with acute myocardial …
remain challenging due to symptomatic hypotension in patients with acute myocardial …
[HTML][HTML] Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction
P Yang, X Li, L Wang, X Wu, C Wang, T Li… - Frontiers in …, 2023 - frontiersin.org
Introduction In 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to
Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that …
Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that …
The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction
P Martens, H Beliën, M Dupont… - Cardiovascular …, 2018 - Wiley Online Library
Background Major classes of medical therapy for heart failure with reduced ejection fraction
(HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan …
(HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan …
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
BACKGROUND: The VALIANT trial compared the efficacy and safety of captopril, valsartan,
and their combination in patients with left ventricular systolic dysfunction, heart failure, or …
and their combination in patients with left ventricular systolic dysfunction, heart failure, or …
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan
Background Left ventricular (LV) remodelling is a major mechanism underlying disease
progression in patients with heart failure (HF) with reduced ejection fraction (EF). Previous …
progression in patients with heart failure (HF) with reduced ejection fraction (EF). Previous …